HAG
NKTR icon

HighPoint Advisor Group’s Nektar Therapeutics NKTR Stock Holding History

HighPoint Advisor Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-605
Closed -$181K – 443
2019
Q3 		$181K Sell
605
-335
-36% -$123K 0.04% 334
2019
Q2 		$455K Buy
940
+27
+3% +$13.5K 0.11% 165
2019
Q1 		$439K Buy
913
+7
+0.8% +$4.15K 0.11% 175
2018
Q4 		$581K Buy
906
+180
+25% +$109K 0.15% 146
2018
Q3 		$435K Sell
726
-30
-4% -$25.6K 0.12% 179
2018
Q2 		$680K Buy
756
+302
+67% +$348K 0.18% 138
2018
Q1 		$369K Buy
+454
New +$585K 0.1% 206
2017
Q4 		– Sell
-1,220
Closed -$431K – 313
2017
Q3 		$431K Buy
+1,220
New +$382K 0.13% 177

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

HighPoint Advisor Group's NKTR Position: Q4 2019 in Review

HighPoint Advisor Group sold out of Nektar Therapeutics (NKTR) in Q4 2019, closing a stake of 605 shares — an estimated $181K sold.

HighPoint Advisor Group first reported a position in NKTR in Q3 2017 and held it in 8 quarters. The position peaked at $680K in Q2 2018. 281 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

  • HighPoint Advisor Group reported no remaining Nektar Therapeutics position as of Q4 2019 after selling out during the quarter.
  • HighPoint Advisor Group sold 605 Nektar Therapeutics shares in Q4 2019, an estimated $181K.
  • HighPoint Advisor Group first reported a position in Nektar Therapeutics in Q3 2017 and held it in 8 quarters.
  • HighPoint Advisor Group's Nektar Therapeutics position peaked at $680K in Q2 2018.
  • 281 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on HighPoint Advisor Group's 13F filing for Q4 2019, filed 13 Feb 2020.